Invesco
GPCR icon

Invesco’s Structure Therapeutics GPCR Stock Holding History

Invesco’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
3,951
-630
-14% -$27.9K ﹤0.01% 3576
2026
Q1 		$221K Buy
4,581
+1,381
+43% +$94.5K ﹤0.01% 3454
2025
Q4 		$223K Sell
3,200
-440,537
-99% -$18M ﹤0.01% 3488
2025
Q3 		$12.4M Buy
443,737
+19,189
+5% +$382K ﹤0.01% 1692
2025
Q2 		$8.81M Buy
424,548
+30,162
+8% +$663K ﹤0.01% 1859
2025
Q1 		$6.83M Buy
394,386
+22,619
+6% +$554K ﹤0.01% 2006
2024
Q4 		$10.1M Buy
371,767
+14,559
+4% +$517K ﹤0.01% 1854
2024
Q3 		$15.7M Buy
357,208
+119,234
+50% +$4.61M ﹤0.01% 1599
2024
Q2 		$9.35M Buy
237,974
+25,900
+12% +$1.06M ﹤0.01% 1829
2024
Q1 		$9.09M Buy
212,074
+16,447
+8% +$694K ﹤0.01% 1874
2023
Q4 		$7.97M Buy
195,627
+82,534
+73% +$4.73M ﹤0.01% 1960
2023
Q3 		$5.7M Buy
+113,093
New +$3.64M ﹤0.01% 2132

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Invesco's GPCR Position: Q2 2026 in Review

Invesco reduced its Structure Therapeutics (GPCR) stake by 14% in Q2 2026, selling an estimated $27.9K and leaving 3,951 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #3576.

Invesco first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $15.7M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Invesco held 3,951 shares of Structure Therapeutics worth $212K as of Q2 2026.
  • Invesco sold 630 Structure Therapeutics shares in Q2 2026, an estimated $27.9K.
  • Structure Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3576 holding.
  • Invesco first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Invesco's Structure Therapeutics position peaked at $15.7M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.